Accept Cookies?
Provided by OpenGlobal E-commerce

Please wait while your page loads ...

LEXEO Therapeutics Receives Rare Pediatric Disease Designation and Orphan Drug Designation.

NEW YORK – June 30, 2021 (GLOBE NEWSWIRE) – LEXEO Therapeutics, a clinical-stage gene therapy company, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease designation and Orphan Drug designation to LX2006 for the treatment of Friedreich’s ataxia (FA). LX2006 is an IV-administered, adeno-associated virus (AAV)-mediated gene therapy encoding the human frataxin gene. The designations granted to LX2006 cover cardiac disease and broader symptoms associated with FA.

Read the Full article here


SHARE
 

Scientific News Archives

Tagged in
Scientific News

Beaker

Privacy Policy      Service Terms      Contact      Charity Navigator